New NIH repurposed therapeutics trial
Just 14 months after the pandemic started, the NIH has decided to start a massive RCT (n=13,500) on repurposed drugs – the drugs are un-named as of yet – to try and “figure out” if any repurposed drugs can treat mild/moderate cases of COVID19.
Cost: $155 million.
Your Tax Dollars At Work, and a short, short 14 months after the pandemic started! It really doesn’t get any better than this. Especially given who is in charge of the NIH therapeutics panel, and where those guys get their grant money from. Seriously. This really IS the best they can do, given the oppressive burden of systemic sociopathy and financial conflict they must all operate under.
The only question I have is – just how is this trial designed to fail? Let’s look at the details:
…Drugs will be administered orally or by inhaler and will be easy for participants to take at home. Participants will be assigned randomly to receive either a placebo or one of the treatments, which will be sent to them by mail.
Enrollment is expected to open in a few weeks to up to 13,500 participants who are at least 30 years old, have tested positive for SARS-CoV-2 infection and have experienced two or more mild-to-moderate symptoms of COVID-19 for no more than seven days. Researchers plan to assess changes in patients’ symptoms over a 14-day period, as well as hospitalizations and deaths over a 28-day period. They also will assess long-term COVID-19-related symptoms at 90 days after treatment begins. The list of drugs that will be added to the study arms is still being finalized. All the drugs will have established safety records and early indications from smaller or less controlled studies of effectiveness against COVID-19.
So let’s see. Merck told us, just a few days back, that they were restructuring their Molnupiravir trial such that patients had to be given the anti-viral treatment early in the course of the disease for it to have any effect. Specifically, within 5 days of symptom onset. Merck tried 7 days, and it didn’t work!
But of course in the new NIH trial, we are back to that 7 days of symptom onset, to which you must add the delay in mailing the drugs to the subjects of the trial.
So call it 2-8 or 3-9 days from symptom onset, roughly speaking.
[Could they hand out the drugs at a testing center? Of course they could. Could they restrict it to 1-5 days of symptom onset? Of course they could. Duh.]
As we know, anti-virals need to be given early. MERCK JUST TOLD US THIS. But of course the NIH-Gang from Gilead has decided to ignore this known set of facts for their $155 million trial testing out repurposed cheap drugs that otherwise might work.
That’s how they have designed the trial to fail. Paid for by You and Me.
But you can’t really blame the NIH-Gang from Gilead for their acts of systemic sociopathy. The sociopathy is systemic, after all. Individual acts of sociopathy aren’t really their fault. And besides – how else could Molnupiravir possibly compete? Pharma gonna Pharma. Peons just gotta suck it up. You should be thankful for any trial on cheap drugs that might work. Even with a time horizon that works hard to guarantee they won’t show benefit.
What’s more, this will buy them at least another 4-6 months. Long (90-day) endpoints will see to that. I’m guessing this new trial will wrap up right around the time Merck’s Molnupiravir trial will finish. I’ll know for sure when the trial description appears.
Still, they are starting to show some hints of fear. 14 months in.
So that’s a plus.
They are really gonna need that razor wire, once the truth comes out.
All of this is just so depressing. 🙁
We all knew that common sense wasn’t all that common, but now it’s outright in unicorn land.
“What’s more, this will buy them at least another 4-6 months.”
This is the one conclusion that seems the most consistent with everything that happens: Keep the crisis going.
Reminds me a bit of something I learned during the Clinton administration. I was pretty young but I just couldn’t believe Bill was fighting things where it seemed like he had no chance of winning.
What I learned is that anything can happen if you can keep the process alive. Just keep it going…
I guess all those completed trials by black and brown bodies aren’t good enough for NIH.
I hate the race huskers but at least they might consider being consistent. Why should we waste tax dollars repeating trials that have already been done?
NIH has lost all credibility no matter what they do. Bureaucratic mumbo-jumbo and slight of hand.
As far as I am concerned the studies that were done earlier on black and brown bodies are successful in demonstrating the effectiveness of certain anti-virals. That is what I base my protocols on. Anything the NIH does to “study” the question is irrelevant to me.